Y. Nagata

发表

Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.

Teruyuki Nishimura, K. Kamata, M. Mitsuya, 2004, Structure.

Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators.

K. Kamata, M. Mitsuya, T. Nishimura, 2009, Bioorganic & medicinal chemistry letters.

Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators.

M. Ishikawa, Y. Ogino, T. Nishimura, 2009, Bioorganic & medicinal chemistry letters.

Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs

J. Berger, A. Kadotani, K. Fujii, 2011, Molecular Pharmacology.

Clinical studies on a newly devised amino acid solution for neonates.

S. Kamata, A. Okada, A. Kubota, 1988, JPEN. Journal of parenteral and enteral nutrition.

An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism*

A. Kadotani, T. Nishimura, J. Eiki, 2006, Journal of Biological Chemistry.

Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy.

N. Hashimoto, M. Chiba, T. Nishimura, 2009, Bioorganic & medicinal chemistry.

Effects of simvastatin (MK-733) on branched pathway of mevalonate.

Y. Nagata, T. Kamei, F. Ishida, 1990, Japanese journal of pharmacology.

Metabolic impact of overexpression of liver glycogen synthase with serine-to-alanine substitutions in rat primary hepatocytes.

A. Kadotani, Takao Nakamura, A. Kanatani, 2007, Archives of biochemistry and biophysics.

Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators.

K. Kamata, M. Mitsuya, T. Nishimura, 2009, Bioorganic & medicinal chemistry letters.

In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells

Y. Nagata, T. Kikuchi, T. Abe, 1997, Journal of Neuro-Oncology.

N-[2-[N'-pentyl-(6,6-dimethyl-2,4-heptadiynyl)amino]ethyl]- (2-methyl-1-naphthylthio)acetamide (FY-087). A new acyl coenzyme a:cholesterol acyltransferase (ACAT) inhibitor of diet-induced atherosclerosis formation in mice.

Y. Iwasawa, Y. Nagata, M. Yonemoto, 1995, Biochemical pharmacology.

Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.

M. Chiba, K. Kamata, T. Nishimura, 2009, Bioorganic & medicinal chemistry.

Glucokinase is a critical regulator of ventromedial hypothalamic neuronal glucosensing.

V. Routh, L. Gaspers, B. Levin, 2006, Diabetes.

Effects of NB-598, a potent squalene epoxidase inhibitor, on the apical membrane uptake of cholesterol and basolateral membrane secretion of lipids in Caco-2 cells.

Y. Iwasawa, A. Shimizu, Y. Nagata, 1993, Biochemical pharmacology.

NB-598: a potent competitive inhibitor of squalene epoxidase.

Y. Iwasawa, M. Hayashi, Y. Sawasaki, 1990, The Journal of biological chemistry.

The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators.

N. Hashimoto, K. Kamata, T. Nishimura, 2009, Bioorganic & medicinal chemistry.

Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators.

M. Chiba, K. Kamata, M. Mitsuya, 2009, Bioorganic & medicinal chemistry letters.

Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.

Y. Iwasawa, Y. Nagata, T. Kamei, 1991, The Journal of biological chemistry.

An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells.

M. Hayashi, Y. Nagata, T. Satoh, 1993, Biochimica et biophysica acta.

Effect of an inhibitor of squalene epoxidase, NB-598, on lipid metabolism in Hep G2 cells.

M. Hayashi, Y. Nagata, M. Yonemoto, 1992, Chemical & pharmaceutical bulletin.